Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 589309 | 7 pages | https://doi.org/10.1155/2013/589309

Decrease of Obesity by Allantoin via Imidazoline I1-Receptor Activation in High Fat Diet-Fed Mice

Academic Editor: Karen M. von Deneen
Received05 Jan 2013
Revised16 Feb 2013
Accepted04 Mar 2013
Published31 Mar 2013

Abstract

The activation of the imidazoline I1-receptor (I1R) is known to regulate appetite. Allantoin, an active ingredient in the yam, has been reported to improve lipid metabolism in high fat diet- (HFD-)fed mice. However, the effect of allantoin on obesity remains unclear. In the present study, we investigated the effects of allantoin on HFD-induced obesity. The chronic administration of allantoin to HFD-fed mice for 8 weeks significantly decreased their body weight, and this effect was reversed by efaroxan at a dose sufficient to block I1R. The epididymal white adipose tissue (eWAT) cell size and weight in HFD-fed mice were also decreased by allantoin via the activation of I1R. In addition, allantoin significantly decreased the energy intake of HFD-fed mice, and this reduction was associated with a decrease in the NPY levels in the brain. However, no inhibitory effect of allantoin on energy intake was observed in db/db mice. Moreover, allantoin lowered HFD-induced hyperleptinemia, and this activity was abolished by I1R blockade with efaroxan. Taken together, these data suggest that allantoin can ameliorate energy intake and eWAT accumulation by activating I1R to improve HFD-induced obesity.

1. Introduction

Obesity is a major health problem. It is a leading cause of metabolic syndrome, and its prevalence worldwide has increased throughout the 21st century [13]. Obesity is associated with an increased risk of many complications, such as cardiovascular disease, type 2 diabetes, and certain types of cancer [4, 5]. Physical exercise, diet restriction, and medication are the major ways to improve obesity [68], but their effectiveness remains limited. Some studies have shown that certain herbal agents have antiobesity effects [9, 10]. Thus, the development of an alternative agent for the treatment of obesity is necessary.

Allantoin is known as an active ingredient in the yam (Dioscorea spp.) [11]. The yam (Dioscorea rhizome) contains ureides, including allantoin, which are used to prevent inflammation [12, 13]. The yam is a common plant that is widely used in agriculture and in the drug industry. Recently, some herbs from the Dioscoreaceae have been shown to improve the symptoms of metabolic diseases via antihyperlipidemic and antioxidative effects [14, 15]. Allantoin has been shown to activate the imidazoline I1-receptor (I1R) in animal models and cell lines [16]. In addition, allantoin attenuates hyperlipidemia and improves hepatic steatosis via the activation of I1R to regulate farnesoid X receptor (FXR), demonstrating that I1R is involved in lipid homeostasis [16]. However, the effects of allantoin on obesity remain obscure. Thus, in the present study, we investigated the effect of allantoin on high-fat diet- (HFD-)induced obesity and the potential mechanism(s) underlying its activity.

2. Materials and Methods

2.1. Induction of Obesity in HFD-Fed Mice

Eight-week-old male C57BL/6 mice (20–25 g) obtained from the Animal Center of National Cheng Kung University Medical College were housed in a temperature-controlled room (25 ± 1°C) under a 12:12-h light:dark cycle (light on at 06:00 h). The mice were divided into two groups. One group was fed with a standard laboratory diet (3.04 kcal/g), and the other group was fed with a high-calorie diet containing 5.16 kcal/g (TestDiet, Richmond, IN, USA) for 12 weeks to induce obesity and metabolic disorders. The db/db mice were obtained from Japan SLC, Inc. (Shizuoka, Japan). All animal procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, as well as the guidelines of the Animal Welfare Act.

2.2. Measurement of Body Weight and Energy Intake

In preliminary experiments, allantoin (Sigma-Aldrich, St. Louis, MO, USA) decreased the body weight of mice fed a HFD. Its activity increased gradually and reached a stable plateau at 8 weeks. Thus, HFD-fed mice were treated with allantoin three times a day for 8 weeks, and body weight was measured at baseline (0 week) and at the 2nd, 4th, 6th, and 8th weeks of the experiment. In addition, the daily energy intake was calculated based on the consumption of normal chow (3.04 kcal/g) or HFD (5.16 kcal/g).

2.3. Measurement of Energy Intake in db/db Mice

Mice were food-deprived overnight for 12 h (8 pm–8 am). The mice were weighed and then intraperitoneally injected with either vehicle or allantoin prior to the provision of food. Each mouse was maintained isolation in a cage. The energy intake was calculated over 4 h as described previously [17].

2.4. Measurement of Epididymal White Adipose Tissues

At the end of the experimental period, the mice were sacrificed under 3% isoflurane anesthesia. The epididymal white adipose tissues (eWAT) were isolated and weighed. Then, the eWAT ratio was calculated relative to the body weight of each individual.

2.5. Immunosorbent Assay for NPY Levels

The hypothalamus was isolated from sacrificed mice, and the NPY concentration was determined. The obtained samples were homogenized at 4°C in ice-cold homogenization buffer containing 10 mM Tris-HCl (pH 7.4), 20 mM EDTA, 10 mM EGTA, 20 mM -glycerolphosphate, 50 mM NaF, 50 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 25  g/mL leupeptin, and 25 μg/mL aprotinin—protease inhibitors in a Teflon/glass homogenizer. The homogenate was centrifuged at 6000  g for 20 min at 4°C, and the supernatant was used for NPY quantification. The NPY in each sample was measured using a commercially available mouse enzyme-linked immunosorbent assay (Phoenix Europe GmbH, Karlsruhe, Germany). The absorbance was measured in a SpectraMax 340PC ELISA reader (Molecular Devices Corporation, Union City, CA, USA) at 450 nm.

2.6. Determination of Leptin Levels

The mice were fasted for 12 h and anesthetized. Blood samples were collected from the retro-orbital sinuses of each group. The blood samples were then centrifuged at 3,000 rpm for 10 min. Then, the leptin concentration was determined using enzyme-linked immunosorbent assay (ELISA). According to the assay procedure, the determination of leptin in samples was carried out using a commercially available mouse ELISA kit (Assaypro, St. Charles, MO, USA). The absorbance was measured by a SpectraMax 340PC ELISA reader (Molecular Devices Corporation, Union City, CA, USA) at 450 nm.

2.7. Histological Analysis

The epididymal white adipose tissues were removed from each group of mice and fixed in 10% formaldehyde at 4°C for 2 days. Fixed specimens were dehydrated and embedded in paraffin. The specimens were then cut into 5  m thick sections at 50  m intervals and stained with hematoxylin and eosin (H and E; Muto Pure Chemicals, Tokyo, Japan). The sections were observed under a light microscope.

2.8. Statistical Analysis

All values are presented as the mean ± SEM from one group of animals or samples. Analysis of variance and Dunnett’s post hoc test were used to evaluate any significant differences between groups. was considered to indicate a significant difference.

3. Results

3.1. The Effect of Allantoin on Body Weight in HFD-Fed Mice

As shown in Figure 1, mice that were fed with the HFD for 3 months showed a marked ( ) increase in body weight (42.00 ± 0.34 g, ) compared with the normal chow-fed mice (26.38 ± 0.44 g, ). The average body weight of HFD-fed mice that received intraperitoneal injections of allantoin (5 mg/kg) three times a day for 8 weeks was significantly reduced compared with that of the vehicle-treated HFD-fed mice (35.38 ± 0.26 g versus 51.00 ± 0.44 g, ). The allantoin-induced decrease in body weight was attenuated by the intraperitoneal injection of efaroxan at a dose (1.5 mg/kg) sufficient to block imidazoline I1-receptors [17].

3.2. Improvement of Epididymal White Adipose Tissue (eWAT) in HFD-Fed Mice by Allantoin

As shown in Figure 2, the HFD significantly induced obesity in mice. The epididymal white adipose tissue (eWAT) cell size in HFD-fed mice was larger than that in normal chow-fed mice. Allantoin ameliorated these changes in eWAT. Pretreatment with efaroxan reversed the distribution and types of eWAT to that of the HFD group, indicating that the activity of allantoin was abolished by efaroxan (Figure 2). Allantoin also decreased the eWAT weight, and this reduction could be reversed by pretreatment with efaroxan. The eWAT ratio also exhibited the same pattern (Table 1).


eWAT (g)eWAT ratio (%)

Normal mice0.85 ± 0.022.70 ± 0.07
HFD-fed mice
 +vehicle2.04 ± 0.03***4.00 ± 0.06***
 +allantoin0.89 ± 0.032.52 ± 0.06
 +efaroxan and allantoin2.02 ± 0.02***3.94 ± 0.06***

The values represent the mean ± SEM of eight animals. The eWAT ratio was calculated by dividing the eWAT weight with body weight for each animal and was expressed as a percentage. *** compared with the normal mice.

3.3. The Involvement of Imidazoline I1-Receptors in the Allantoin-Induced Reduction of Energy Intake

Intraperitoneal injection of allantoin (5 mg/kg) three times a day for 8 weeks markedly reduced the energy intake of HFD-fed mice, from 18.77 ± 1.52 kcal/g/day to 11.29 ± 0.47 kcal/g/day (Figure 3). Pretreatment with efaroxan (1.5 mg/kg, i.p.) abolished this activity. However, treatment with efaroxan alone had no influence on the energy intake of HFD-fed mice.

3.4. Changes in the Neuropeptide Y (NPY) Level in the Hypothalamus of HFD-Fed Mice

As shown in Figure 4, the hypothalamic NPY level in HFD-fed mice was markedly reduced by treatment with allantoin (5 mg/kg, i.p.) for 8 weeks. Pretreatment with efaroxan (1.5 mg/kg i.p.) 30 min before the administration of allantoin abolished this change in hypothalamic NPY (Figure 4).

3.5. Allantoin Activity in db/db Mice

As shown in Figure 5, energy intake was markedly increased in db/db mice. However, the injection of allantoin (5 mg/kg, i.p.) into db/db mice failed to produce changes in energy intake compared with vehicle-treated db/db mice. This indicates that the inhibitory effect of allantoin on energy intake disappeared in db/db mice.

3.6. The Improvement of Hyperleptinemia by Allantoin in HFD-Fed Mice

The administration of allantoin (5 mg/kg, i.p., three times/daily) for 8 weeks significantly decreased the plasma leptin level in HFD-fed mice (Table 2). This decrease was attenuated by pretreatment with efaroxan (1.5 mg/kg i.p.) 30 min before the administration of allantoin.


Leptin (ng/mL)

Normal mice18.84 ± 1.36###
HFD-fed mice
 +vehicle59.83 ± 1.05***
 +allantoin17.21 ± 0.82###
  +efaroxan and allantoin61.86 ± 2.25***

Values were obtained from each group of eight animals and expressed as the mean ± SEM. ***P < 0.001 compared with the normal chow-fed mice group; ###P < 0.001 compared with the vehicle-treated HFD-fed mice group.

4. Discussion

In the present study, we found that allantoin caused a marked decrease in body weight and improved eWAT accumulation and energy intake in HFD-fed mice. This antiobesity action of allantoin was reversed by I1R blockade. These results indicate that allantoin may ameliorate HFD-induced obesity via the activation of I1R.

Adipose tissue content is closely associated with obesity, and eWAT is widely used as an indicator in the investigation of obesity [18, 19]. In the present study, allantoin effectively decreased eWAT cell size (Figure 2) and weight (Table 1) via the activation of I1R. This action of allantoin on eWAT is effective at a dose similar to the dose required to improve hepatic steatosis in HFD-fed mice [16]. Allantoin can thus be considered to affect lipid homeostasis via the activation of I1R [16].

In addition to the role of adipose tissue, energy intake is also important in obesity. Some studies have indicated that imidazoline receptors exert beneficial effects on energy regulation [20, 21]. There are 3 types of imidazoline receptors, named as I1R, I2R and I3R [22, 23]. Previous studies have demonstrated that the activation of I1R may improve hypertension via sympathoinhibition [24]; the activation of I2R may improve insulin resistance via the AMP kinase pathway to enhance glucose uptake in type-2 diabetic animal models [2527]; and the stimulation of I3R may stimulate insulin secretion from pancreatic cells [28]. Although I2R has been reported to regulate monoamine oxidase (MAO) in the brain [29], I3R has not been found in the brain and is expressed mainly in the pancreas [28]. Thus, I2R and I3R seem unlikely to be involved in cerebral energy regulation. I1R is located in mainly the rostroventrolateral medulla of the brain stem, and it has also been identified in the hypothalamus [30, 31]. The activation of I1R has been reported to improve hypertension and hyperlipidemia [16]. Additionally, I1R activation was shown to attenuate hyperphagia in STZ-induced diabetic mice by lowering the hypothalamic NPY level [17], similar to the mechanism observed in Zucker rats [32]. Previous studies demonstrated that appetite was reduced by an increase in blood pressure [33, 34]. However, allantoin decreases appetite at a dose that is sufficient to lower blood pressure [16]. Thus, the change in blood pressure does not seem to be related to the change in feeding behavior caused by allantoin. In the present study, HFD-fed mice showed greater energy intake than did normal chow-fed mice (Figure 3). Allantoin attenuated this increased energy intake via the activation of I1R in HFD-fed mice, and this activity was reversed by I1R blockade with efaroxan [17]. The same dose of efaroxan alone didnot alter the appetite response in mice, indicating that alpha-2 adrenergic receptors, which may modify the feeding behaviors in animal [35, 36], are not involved in its action, and this result is consistent with previously reported data [17]. Clinically, imidazoline receptor agonist(s) are preferred to alpha-2 adrenergic receptor agonist(s) because they do not cause sedation as a side effect [37]. Additionally, imidazoline receptor agonist(s) showed no significant effects on general behavior in animals [38]. Moreover, the hypothalamic NPY level was also reduced by allantoin via I1R activation in HFD-fed mice (Figure 4). Thus, the effectiveness of allantoin in the regulation of energy intake is further characterized in this study.

The adipocyte-derived hormone leptin has established roles in the regulation of energy intake, energy expenditure, and whole-body energy metabolism [39]. HFD-fed mice exhibited marked hyperleptinemia, consistent with a previous report demonstrating their inability to adequately respond to elevated leptin levels [40]. The present study showed that allantoin also decreased plasma leptin levels in HFD-fed mice via I1R activation (Table 2). Additionally, HFD-fed mice showed higher NPY levels, which may be associated with leptin signaling dysfunction [4143]. To determine whether the action of allantoin on the inhibition of energy intake is mediated through endogenous leptin, we studied the energy intake in the db/db mouse, which is deficient for the leptin receptor [44]. As shown in Figure 5, allantoin failed to decrease the energy intake in db/db mice, due to the absence of leptin receptor in this strain. It has been reported that leptin can inhibit NPY secretion in the hypothalamus [45]. Thus, it is reasonable to speculate that the activation of I1R by allantoin may mediate leptin to inhibit hypothalamic NPY for reduction of hyperphagia to result in the decrease of obesity. However, the regulation of hypothalamic NPY level is quite complicated, including roles for proopiomelanocortin (POMC) neurons, the alpha-melanocyte-stimulating hormone ( -MSH), and melanocortin-3 (MC3) receptors [46, 47]. Thus, the detailed mechanism of action of allantoin in HFD-induced obesity requires further investigation in the future.

5. Conclusions

We found that allantoin has antiobesity effects in HFD-fed mice and that these effects are mediated by the activation of I1R, which results in lower energy intake and reduced eWAT accumulation. Thus, allantoin can be used as an alternative agent for the improvement of obesity in the future.

Abbreviations

eWAT:Epididymal white adipose tissue
HFD: High fat diet
: Imidazoline -receptors
IP: Intraperitoneal
NPY: Neuropeptide Y.

Authors’ Contribution

Hsien-Hui Chung and Kung Shing Lee contributed equally to this article.

Acknowledgments

The outhors thank Dr. K. C. Cheng and Mr. K. F. Liu for skillful assistance with these experiments. The present study was funded mainly by a Grant from the National Sciences Council (NSC 99-2628-B309-001-MY3) of Taiwan.

References

  1. R. Hutcheson and P. Rocic, “The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration,” Experimental Diabetes Research, vol. 2012, Article ID 271028, 13 pages, 2012. View at: Publisher Site | Google Scholar
  2. C. Koebnick, N. Smith, K. Huang, M. P. Martinez, H. A. Clancy, and L. H. Kushi, “The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California,” Annals of Epidemiology, vol. 22, no. 9, pp. 609–616, 2012. View at: Google Scholar
  3. R. Woodhouse, “Obesity in art—a brief overview,” Frontiers of Hormone Research, vol. 36, pp. 271–286, 2008. View at: Publisher Site | Google Scholar
  4. D. W. Haslam and W. P. T. James, “Obesity,” The Lancet, vol. 366, no. 9492, pp. 1197–1209, 2005. View at: Publisher Site | Google Scholar
  5. M. J. Müller, M. Lagerpusch, J. Enderle, B. Schautz, M. Heller, and A. Bosy-Westphal, “Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome,” Obesity Reviews, vol. 13, supplement 2, pp. 6–13, 2012. View at: Google Scholar
  6. N. L. Novak and K. D. Brownell, “Obesity: a public health approach,” The Psychiatric Clinics of North America, vol. 34, no. 4, pp. 895–909, 2011. View at: Google Scholar
  7. G. Dubnov-Raz and E. M. Berry, “The dietary treatment of obesity,” The Medical Clinics of North America, vol. 95, no. 5, pp. 939–952, 2011. View at: Google Scholar
  8. A. J. Scheen and P. Ernest, “New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat,” Diabetes and Metabolism, vol. 28, no. 6, part 1, pp. 437–445, 2002. View at: Google Scholar
  9. M. L. Mollah, G. S. Kim, H. K. Moon et al., “Antiobesity effects of wild ginseng (Panax ginseng C.A. meyer) mediated by PPAR-γ, GLUT4 and LPL in ob/ob mice,” Phytotherapy Research, vol. 23, no. 2, pp. 220–225, 2009. View at: Publisher Site | Google Scholar
  10. N. Vasudeva, N. Yadav, and S. K. Sharma, “Natural products: a safest approach for obesity,” The Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 473–480, 2012. View at: Google Scholar
  11. K. Sagara, M. Ojima, K. Suto, and T. Yoshida, “Quantitative determination of allantoin in Dioscorea rhizome and an oriental pharmaceutical preparation, Hachimi-Gan, by high-performance liquid chromatography,” Planta Medica, vol. 55, no. 1, article 93, 1989. View at: Google Scholar
  12. A. V. Shestopalov, T. P. Shkurat, Z. I. Mikashinovich et al., “Biological functions of allantoin,” Izvestiia Akademii Nauk Seriia Biologicheskaia, no. 5, pp. 541–545, 2006. View at: Google Scholar
  13. M. Y. Lee, N. H. Lee, D. Jung et al., “Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma,” International Immunopharmacology, vol. 10, no. 4, pp. 474–480, 2010. View at: Publisher Site | Google Scholar
  14. W. C. Chang, Y. M. Yu, C. H. Wu, Y. H. Tseng, and K. Y. Wu, “Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome,” The Canadian Journal of Physiology and Pharmacology, vol. 83, no. 5, pp. 423–430, 2005. View at: Publisher Site | Google Scholar
  15. T. Wang, R. C. Choi, J. Li et al., “Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress,” Journal of Ethnopharmacology, vol. 139, no. 1, pp. 214–220, 2012. View at: Google Scholar
  16. T. T. Yang, N. H. Chiu, H. H. Chung, C. T. Hsu, W. J. Lee, and J. T. Cheng, “Stimulatory effect of allantoin on imidazoline i1 receptors in animal and cell line,” Hormone and Metabolic Research, vol. 44, no. 12, pp. 879–884, 2012. View at: Google Scholar
  17. H. H. Chung, T. T. Yang, M. F. Chen, M. T. Chou, and J. T. Cheng, “Improvement of hyperphagia by activation of cerebral I(1)-imidazoline receptors in streptozotocin-induced diabetic mice,” Hormone and Metabolic Research, vol. 44, no. 9, pp. 645–649, 2012. View at: Google Scholar
  18. K. Matsumoto, Y. Watanabe, and S. I. Yokoyama, “Okara, soybean residue, prevents obesity in a diet-induced murine obesity model,” Bioscience, Biotechnology and Biochemistry, vol. 71, no. 3, pp. 720–727, 2007. View at: Publisher Site | Google Scholar
  19. A. Bartolomucci, E. Bresciani, I. Bulgarelli et al., “Chronic intracerebroventricular injection of TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice,” Genes and Nutrition, vol. 4, no. 1, pp. 49–57, 2009. View at: Publisher Site | Google Scholar
  20. C. S. Niu, H. T. Wu, K. C. Cheng, K. C. Lin, C. T. Chen, and J. T. Cheng, “A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice,” Hormone and Metabolic Research, vol. 43, no. 7, pp. 458–463, 2011. View at: Publisher Site | Google Scholar
  21. P. S. Yang, H. T. Wu, H. H. Chung et al., “Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 1, pp. 51–56, 2012. View at: Google Scholar
  22. N. V. Gongadze, N. A. Antelava, and T. D. Kezeli, “Imidazoline receptors,” Georgian medical news, no. 160-161, pp. 44–47, 2008. View at: Google Scholar
  23. G. A. Head and D. N. Mayorov, “Imidazoline receptors, novel agents and therapeutic potential,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 4, no. 1, pp. 17–32, 2006. View at: Publisher Site | Google Scholar
  24. G. A. Head, S. L. Burke, and C. K. Chan, “Site and receptors involved in the sympathoinhibitory actions of rilmenidine,” Journal of Hypertension, Supplement, vol. 16, no. 3, pp. S7–S12, 1998. View at: Google Scholar
  25. W. C. Ko, I. M. Liu, H. H. Chung, and J. T. Cheng, “Activation of I2-imidazoline receptors may ameliorate insulin resistance in fructose-rich chow-fed rats,” Neuroscience Letters, vol. 448, no. 1, pp. 90–93, 2008. View at: Publisher Site | Google Scholar
  26. C. H. Su, I. M. Liu, H. H. Chung, and J. T. Cheng, “Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats,” Neuroscience Letters, vol. 457, no. 3, pp. 125–128, 2009. View at: Publisher Site | Google Scholar
  27. T. T. Yang, P. M. Ku, C. T. Hsu, H. H. Chung, W. J. Lee, and J. T. Cheng, “Mediation of AMP kinase in the increase of glucose uptake in L6 cells induced by activation of imidazoline I-2 receptors,” Hormone and Metabolic Research, 2013. View at: Publisher Site | Google Scholar
  28. N. G. Morgan and S. L. F. Chan, “Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?” Current Pharmaceutical Design, vol. 7, no. 14, pp. 1413–1431, 2001. View at: Publisher Site | Google Scholar
  29. N. J. Anderson, P. A. Lupo, D. J. Nutt, A. L. Hudson, and E. S. J. Robinson, “Characterisation of imidazoline I2 binding sites in pig brain,” The European Journal of Pharmacology, vol. 519, no. 1-2, pp. 68–74, 2005. View at: Publisher Site | Google Scholar
  30. A. J. Thomas, B. O. Erokwu, B. K. Yamamoto, P. Ernsberger, O. Bishara, and K. P. Strohl, “Alterations in respiratory behavior, brain neurochemistry and receptor density induced by pharmacologic suppression of sleep in the neonatal period,” Developmental Brain Research, vol. 120, no. 2, pp. 181–189, 2000. View at: Publisher Site | Google Scholar
  31. J. Zhang and A. A. Abdel-Rahman, “Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (I1)-receptor-mediated hypotension,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 945–952, 2005. View at: Publisher Site | Google Scholar
  32. C. Bing, P. King, L. Pickavance et al., “The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones,” The British Journal of Pharmacology, vol. 127, no. 1, pp. 35–42, 1999. View at: Publisher Site | Google Scholar
  33. A. P. Makris, C. R. Rush, R. C. Frederich, and T. H. Kelly, “Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity,” Appetite, vol. 42, no. 2, pp. 185–195, 2004. View at: Publisher Site | Google Scholar
  34. K. Matsumura, T. Tsuchihashi, K. Fujii, and M. Iida, “Neural regulation of blood pressure by leptin and the related peptides,” Regulatory Peptides, vol. 114, no. 2-3, pp. 79–86, 2003. View at: Publisher Site | Google Scholar
  35. P. J. Wellman, “Norepinephrine and the control of food intake,” Nutrition, vol. 16, no. 10, pp. 837–842, 2000. View at: Publisher Site | Google Scholar
  36. S. Stujii and G. A. Bray, “Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists,” Brain Research, vol. 587, no. 2, pp. 226–232, 1992. View at: Publisher Site | Google Scholar
  37. L. P. Edwards, T. A. Brown-Bryan, L. McLean, and P. Ernsberger, “Pharmacological properties of the central antihypertensive agent, moxonidine,” Cardiovascular Therapeutics, vol. 30, no. 4, pp. 199–208, 2012. View at: Google Scholar
  38. V. Panfilov, A. D. Morris, R. Donnelly, M. Scemama, and J. L. Reid, “The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension,” The British Journal of Clinical Pharmacology, vol. 40, no. 6, pp. 563–569, 1995. View at: Google Scholar
  39. J. H. Yu and M. S. Kim, “Molecular mechanisms of appetite regulation,” Diabetes and Metabolism Journal, vol. 36, no. 6, pp. 391–398, 2012. View at: Google Scholar
  40. C. Gallou-Kabani, A. Vigé, M. S. Gross et al., “C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome,” Obesity, vol. 15, no. 8, pp. 1996–2005, 2007. View at: Publisher Site | Google Scholar
  41. E. Jéquier, “Leptin signaling, adiposity, and energy balance,” Annals of the New York Academy of Sciences, vol. 967, pp. 379–388, 2002. View at: Google Scholar
  42. X. M. Guan, H. Yu, M. Trumbauer, E. Frazier, L. H. T. van der Ploeg, and H. Chen, “Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice,” Neuroreport, vol. 9, no. 15, pp. 3415–3419, 1998. View at: Google Scholar
  43. S. O. Kim, S. J. Yun, and E. H. Lee, “The water extract of adlay seed (Coix lachrymajobi var. mayuen) exhibits anti-obesity effects through neuroendocrine modulation,” The American Journal of Chinese Medicine, vol. 35, no. 2, pp. 297–308, 2007. View at: Publisher Site | Google Scholar
  44. R. C. Davis, A. van Nas, L. W. Castellani et al., “Systems genetics of susceptibility to obesity-induced diabetes in mice,” Physiological Genomics, vol. 44, no. 1, pp. 1–13, 2012. View at: Google Scholar
  45. S. S. Dhillon, S. A. McFadden, J. A. Chalmers, M. L. Centeno, G. L. Kim, and D. D. Belsham, “Cellular leptin resistance impairs the leptin-mediated suppression of neuropeptide Y secretion in hypothalamic neurons,” Endocrinology, vol. 152, no. 11, pp. 4138–4147, 2011. View at: Google Scholar
  46. S. Jégou, I. Boutelet, and H. Vaudry, “Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus,” Journal of Neuroendocrinology, vol. 12, no. 6, pp. 501–505, 2000. View at: Publisher Site | Google Scholar
  47. H. Zheng, R. L. Townsend, A. C. Shin, L. M. Patterson, C. B. Phifer, and H. R. Berthoud, “High-fat intake induced by mu-opioid activation of the nucleus accumbens is inhibited by Y1R-blockade and MC3/4R-stimulation,” Brain Research, vol. 1350, pp. 131–138, 2010. View at: Publisher Site | Google Scholar

Copyright © 2013 Hsien-Hui Chung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1478 Views | 620 Downloads | 6 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.